ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers ; volume:18 ; number:6 ; year:2022 ; extent:22
Molecular systems biology ; 18, Heft 6 (2022) (gesamt 22)
- Creator
-
Nath, Aritro
Cohen, Adam L.
Bild, Andrea H.
- DOI
-
10.15252/msb.202110558
- URN
-
urn:nbn:de:101:1-2022060815033125459832
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nath, Aritro
- Cohen, Adam L.
- Bild, Andrea H.
Other Objects (12)
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers
Toxicological Mechanism of Endocrine Disrupting Chemicals: Is Estrogen Receptor Involved?
Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis
Estrogen receptor gene (ESR1) amplification occurs rarely in ovarian cancers
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers
Estrogen receptor-α signaling in post-natal mammary development and breast cancers
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers
Toxicological Mechanism of Endocrine Disrupting Chemicals: Is Estrogen Receptor Involved?
Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis
Estrogen receptor gene (ESR1) amplification occurs rarely in ovarian cancers
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers
Estrogen receptor-α signaling in post-natal mammary development and breast cancers
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers
Toxicological Mechanism of Endocrine Disrupting Chemicals: Is Estrogen Receptor Involved?
Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis
Estrogen receptor gene (ESR1) amplification occurs rarely in ovarian cancers
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies
Paralemmin-1 is over-expressed in estrogen-receptor positive breast cancers
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
Role of BRD4 and histone acetylation in estrogen receptor-positive breast cancers
Estrogen receptor-α signaling in post-natal mammary development and breast cancers